How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases

The development of Alzheimer’s disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before...

Descripción completa

Detalles Bibliográficos
Autores: Ávila Villanueva, Marina, Marcos Dolado, Alberto, Fernández Blázquez, Miguel Ángel
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/130631
Acceso en línea:https://hdl.handle.net/20.500.14352/130631
Access Level:acceso abierto
Palabra clave:Alzheimer’s disease continuum
Modifable risk factors
Precision medicine
Sleep disturbances
Ciencias Biomédicas
32 Ciencias Médicas
id ES_b7f131dbba9fa3bfbefd65d9a755bedb
oai_identifier_str oai:docta.ucm.es:20.500.14352/130631
network_acronym_str ES
network_name_str España
repository_id_str
spelling How to prevent and/or revert Alzheimer’s disease continuum during preclinical phasesÁvila Villanueva, MarinaMarcos Dolado, AlbertoFernández Blázquez, Miguel ÁngelAlzheimer’s disease continuumModifable risk factorsPrecision medicineSleep disturbancesCiencias Biomédicas32 Ciencias MédicasThe development of Alzheimer’s disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before the onset of MCI. Indeed, an early risk factor could promote the appearance of additional ones through a continuum. The presence of various risk factors may trigger specific biomarkers. In this review, we comment on how modifiable risk factors for AD may be reverted, thus correlating with a possible decrease in the specific biomarkers for the disease. Finally, we discuss the development of a suitable AD prevention strategy by targeting modifiable risk factors, thereby increasing the level of “precision medicine” in healthcare systems worldwide.SageUniversidad Complutense de Madrid20232023-06-0120232023-06-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/130631reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/1306312026-06-02T12:44:21Z
dc.title.none.fl_str_mv How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
title How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
spellingShingle How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
Ávila Villanueva, Marina
Alzheimer’s disease continuum
Modifable risk factors
Precision medicine
Sleep disturbances
Ciencias Biomédicas
32 Ciencias Médicas
title_short How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
title_full How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
title_fullStr How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
title_full_unstemmed How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
title_sort How to prevent and/or revert Alzheimer’s disease continuum during preclinical phases
dc.creator.none.fl_str_mv Ávila Villanueva, Marina
Marcos Dolado, Alberto
Fernández Blázquez, Miguel Ángel
author Ávila Villanueva, Marina
author_facet Ávila Villanueva, Marina
Marcos Dolado, Alberto
Fernández Blázquez, Miguel Ángel
author_role author
author2 Marcos Dolado, Alberto
Fernández Blázquez, Miguel Ángel
author2_role author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv Alzheimer’s disease continuum
Modifable risk factors
Precision medicine
Sleep disturbances
Ciencias Biomédicas
32 Ciencias Médicas
topic Alzheimer’s disease continuum
Modifable risk factors
Precision medicine
Sleep disturbances
Ciencias Biomédicas
32 Ciencias Médicas
description The development of Alzheimer’s disease (AD) follows three consecutive phases: namely preclinical, prodromal or mild cognitive impairment (MCI), and dementia. In addition, the preclinical phase can be divided into subphases related to the presence of biomarkers that appear at different points before the onset of MCI. Indeed, an early risk factor could promote the appearance of additional ones through a continuum. The presence of various risk factors may trigger specific biomarkers. In this review, we comment on how modifiable risk factors for AD may be reverted, thus correlating with a possible decrease in the specific biomarkers for the disease. Finally, we discuss the development of a suitable AD prevention strategy by targeting modifiable risk factors, thereby increasing the level of “precision medicine” in healthcare systems worldwide.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-06-01
2023
2023-06-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/130631
url https://hdl.handle.net/20.500.14352/130631
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sage
publisher.none.fl_str_mv Sage
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417570288795648
score 15,811543

Similares en LA Referencia